Neuren receives grant of composition patent in Europe for NNZ-2591

Melbourne, Australia, 30 November 2015: Neuren Pharmaceuticals (ASX: NEU) today announced that the European Patent Office has confirmed the grant of a new patent covering the composition of Neuren’s drug candidate NNZ-2591.

The new patent, entitled “Neuroprotective Bicyclic Compounds and Methods for their Use”, will expire in August 2024, with the potential to extend protection in European Union countries for up to 5 years through Supplementary Protection Certificates. Similar patents covering the composition of NNZ-2591 have previously been issued in the United States and Japan. Three additional patents have also been issued in the United States, covering methods for treating Parkinson’s disease, peripheral neuropathy and cognitive impairment. An international application is pending covering methods for treating autism spectrum disorders and neurodevelopmental disorders.

NNZ-2591 is a dipeptide with excellent oral bioavailability and potential for improved stability compared with other peptide-like compounds. It exhibits potent neuroprotective, neurorestorative and pro-cognitive effects, which result from inhibition of inflammation and cell death as well as normalization of synaptic plasticity and neuronal signaling. NNZ-2591 has shown efficacy in pre-clinical models of Parkinson’s disease, stroke, traumatic brain injury, peripheral neuropathy, Fragile X syndrome, memory impairment and multiple sclerosis.

About Neuren

Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. The novel drugs target chronic conditions as well as acute neurological injuries. Neuren presently has a clinical stage molecule, trofinetide in Phase 2 clinical trials as well as NNZ-2591 in pre-clinical development.

Forward-looking Statements

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.

For more information, please contact:
Dr Richard Treagus, Executive Chairman: rtreagus@neurenpharma.com ; +61 417 520 509